Automate Your Wheel Strategy on NEPH
With Tiblio's Option Bot, you can configure your own wheel strategy including NEPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NEPH
- Rev/Share 1.5739
- Book/Share 0.9055
- PB 5.3008
- Debt/Equity 0.1293
- CurrentRatio 5.4052
- ROIC 0.1211
- MktCap 50882899.0
- FreeCF/Share 0.1884
- PFCF 25.4797
- PE 38.3436
- Debt/Assets 0.1014
- DivYield 0
- ROE 0.1489
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Nephros Launches New PFAS Filter for Point-of-Use Protection of Potable Water
NEPH
Published: October 08, 2025 by: MCAP MediaWire
Sentiment: Neutral
Published: October 08, 2025 by: MCAP MediaWire
Sentiment: Neutral
New 19-Series solution targets wide range of chemical contaminants SOUTH ORANGE, NJ, October 8, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Nephros, Inc.
Read More
About Nephros, Inc. (NEPH)
- IPO Date 2004-09-21
- Website https://www.nephros.com
- Industry Medical - Instruments & Supplies
- CEO Robert Banks
- Employees 31
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.